Marisa Wexler, MS, senior science writer —

Top-line results are expected next month for the SPAN clinical trial, a Phase 2 study testing First Wave BioPharma‘s new formulation of adrulipase to treat exocrine pancreatic insufficiency (EPI) in people with cystic fibrosis (CF). The trial’s target enrollment has been reached, with 13 total participants signed on,…

Long-term treatment with Trikafta leads to sustained improvements in lung function, easing of respiratory symptoms, and better nutritional status for people with cystic fibrosis (CF) who have at least one copy of the F508del mutation. That’s according to new data presented by the therapy’s developer Vertex Pharmaceuticals…

Rates of screening for diabetes among people with cystic fibrosis (CF) are not where they should be, a new study reports. “Studies to improve our approach to [CF-related diabetes] screening are urgently needed,” the researchers wrote in “A provider survey of cystic fibrosis related diabetes screening and…

For people with cystic fibrosis (CF), key barriers to getting specialty care include concerns about addiction and affordability, according to a new survey of clinicians. In fact, more than one-third of respondents cited difficulties for CF patients in accessing specialists and issues with insurance and treatment costs. “In this…

For people with cystic fibrosis (CF) taking Pulmozyme (dornase alfa), adding treatment with hypertonic saline — or HS for short — did not significantly improve lung function or reduce the risk of exacerbations compared with the approved therapy alone, a new study indicates. The findings showed that…

Among children with cystic fibrosis (CF), lung function was seen to worsen faster following a bacterial infection with Pseudomonas aeruginosa, especially if the infection became chronic or ongoing, a new study reports. The link between the bacterium — commonly known as Pseudomonas or P. aeruginosa — and a…

TAVT-135, an inhaled treatment candidate being developed for people with cystic fibrosis (CF) regardless of their underlying mutation type, was found to help normalize mucus production in a cell model of the disease. According to researchers from Tavanta Therapeutics, the treatment’s developer, the findings of their in vitro…

Scientists in New York are calling on the cystic fibrosis (CF) research community to take proactive steps to increase diversity in clinical trials — which now typically include a disproportionate number of non-Hispanic white people, and fewer patients from other racial and ethnic backgrounds. “Ensuring that pwCF [people with…

High blood sugar can impair the ability to utilize oxygen for energy with cystic fibrosis (CF), which may explain why exercise can be especially tiring for those with the disease, a new study shows. Researchers think the biological mechanism responsible for this phenomenon is that high blood sugar can…

A class of therapies called PDE4 inhibitors, which are approved to manage certain inflammatory diseases, may help boost the functionality of the protein whose defect causes cystic fibrosis (CF), according to a new study. Results also suggest that some available CF treatments may be effective in a broader array…